Literature DB >> 25246611

Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.

Antonio F Di Narzo1, Sabine Tejpar1, Simona Rossi1, Pu Yan1, Vlad Popovici1, Pratyaksha Wirapati1, Eva Budinska1, Tao Xie1, Heather Estrella1, Adam Pavlicek1, Mao Mao1, Eric Martin1, Weinrich Scott1, Fred T Bosman1, Arnaud Roth1, Mauro Delorenzi2.   

Abstract

BACKGROUND: Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging system. We investigated if four well-documented gene expression risk scores can improve patient stratification.
METHODS: Microarray-based versions of risk-scores were applied to a large independent cohort of 688 stage II/III tumors from the PETACC-3 trial. Prognostic value for relapse-free survival (RFS), survival after relapse (SAR), and overall survival (OS) was assessed by regression analysis. To assess improvement over a reference, prognostic model was assessed with the area under curve (AUC) of receiver operating characteristic (ROC) curves. All statistical tests were two-sided, except the AUC increase.
RESULTS: All four risk scores (RSs) showed a statistically significant association (single-test, P < .0167) with OS or RFS in univariate models, but with HRs below 1.38 per interquartile range. Three scores were predictors of shorter RFS, one of shorter SAR. Each RS could only marginally improve an RFS or OS model with the known factors T-stage, N-stage, and microsatellite instability (MSI) status (AUC gains < 0.025 units). The pairwise interscore discordance was never high (maximal Spearman correlation = 0.563) A combined score showed a trend to higher prognostic value and higher AUC increase for OS (HR = 1.74, 95% confidence interval [CI] = 1.44 to 2.10, P < .001, AUC from 0.6918 to 0.7321) and RFS (HR = 1.56, 95% CI = 1.33 to 1.84, P < .001, AUC from 0.6723 to 0.6945) than any single score.
CONCLUSIONS: The four tested gene expression-based risk scores provide prognostic information but contribute only marginally to improving models based on established risk factors. A combination of the risk scores might provide more robust information. Predictors of RFS and SAR might need to be different.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25246611     DOI: 10.1093/jnci/dju247

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer.

Authors:  Jeroen Declercq; Bart Jacobs; Bart Biesmans; Arnaud Roth; Dirk Klingbiel; Sabine Tejpar; John W Creemers
Journal:  Biomed Res Int       Date:  2015-06-07       Impact factor: 3.411

2.  Quantitative risk stratification of oral leukoplakia with exfoliative cytology.

Authors:  Yao Liu; Jianying Li; Xiaoyong Liu; Xudong Liu; Waqaar Khawar; Xinyan Zhang; Fan Wang; Xiaoxin Chen; Zheng Sun
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

3.  Quantitative prediction of oral cancer risk in patients with oral leukoplakia.

Authors:  Yao Liu; Yicheng Li; Yue Fu; Tong Liu; Xiaoyong Liu; Xinyan Zhang; Jie Fu; Xiaobing Guan; Tong Chen; Xiaoxin Chen; Zheng Sun
Journal:  Oncotarget       Date:  2017-07-11

4.  Building personalized treatment plans for early-stage colorectal cancer patients.

Authors:  Hung-Hsin Lin; Nien-Chih Wei; Teh-Ying Chou; Chun-Chi Lin; Yuan-Tsu Lan; Shin-Ching Chang; Huann-Sheng Wang; Shung-Haur Yang; Wei-Shone Chen; Tzu-Chen Lin; Jen-Kou Lin; Jeng-Kai Jiang
Journal:  Oncotarget       Date:  2017-02-21

Review 5.  Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer.

Authors:  Luigi Laghi; Francesca Negri; Federica Gaiani; Tommaso Cavalleri; Fabio Grizzi; Gian Luigi De' Angelis; Alberto Malesci
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

6.  SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer.

Authors:  A Carmona-Bayonas; V Valentí; P Jiménez-Fonseca; R Salazar
Journal:  ESMO Open       Date:  2021-07-06

Review 7.  Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.

Authors:  Donna M Graham; Vicky M Coyle; Richard D Kennedy; Richard H Wilson
Journal:  Curr Colorectal Cancer Rep       Date:  2016-04-18

8.  Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.

Authors:  Jing Zhu; Natasha G Deane; Keeli B Lewis; Chandrasekhar Padmanabhan; M Kay Washington; Kristen K Ciombor; Cynthia Timmers; Richard M Goldberg; R Daniel Beauchamp; Xi Chen
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

9.  Identification of genes and pathways associated with multiple organ dysfunction syndrome by microarray analysis.

Authors:  Changwei Gu; Wanhai Qiao; Lina Wang; Minmin Li; Kang Song
Journal:  Mol Med Rep       Date:  2018-05-04       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.